NX PRENATAL INC.

Thermo Fisher Scientific Announces Collaboration to Advance Noninvasive Risk Assessments of Pregnancy Outcomes

Retrieved on: 
Tuesday, April 16, 2019
Women's health, RTT, Human reproduction, Obstetrics, Health, Humans, Midwifery, Fertility, Pregnancy, Preterm birth, Childbirth

This new collaboration recognizes the challenges faced by medical professionals who have few tools available for noninvasive risk stratification for adverse pregnancy outcomes.

Key Points: 
  • This new collaboration recognizes the challenges faced by medical professionals who have few tools available for noninvasive risk stratification for adverse pregnancy outcomes.
  • "Our collaboration with NX Prenatal is aiming to enable us to better evaluate maternal and fetal biomarkers during pregnancy that correlate with adverse outcomes, such as preterm birth," said Brad Hart, senior director, clinical research, chromatography and mass spectrometry, Thermo Fisher Scientific.
  • Aberrations in these balances have been shown to correlate with the likelihood of adverse pregnancy outcomes.
  • Ultimately, the analysis has the potential to support obstetrical care decisions in conjunction with traditional clinical assessments.

NX Prenatal Enters Collaboration to Develop High Throughput Clinical Mass Spec Proteomic Assays for NeXosome® Platform

Retrieved on: 
Friday, April 5, 2019
RTT, Fertility, Midwifery, Women's health, Anatomy, Human reproduction, Embryology, Branches of biology, Exosome, Preterm birth, Prenatal development, Childbirth

LOUISVILLE, Ky., April 5, 2019 /PRNewswire/ --NX Prenatal Inc. ("NX Prenatal") today announced that it has entered into a strategic collaboration with Thermo Fisher Scientific.

Key Points: 
  • LOUISVILLE, Ky., April 5, 2019 /PRNewswire/ --NX Prenatal Inc. ("NX Prenatal") today announced that it has entered into a strategic collaboration with Thermo Fisher Scientific.
  • The collaboration is designed to expand upon integrated workflows that the companies have established to enable high volume clinical mass spec proteomic evaluation of plasma samples enriched for exosomes via the NeXosome platform.
  • NX Prenatal's NeXosome technology harvests biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal tissues.
  • The company's proprietary NeXosome platform is being utilized to develop enabling, early warning systems for pregnancies that may result in spontaneous preterm birth, preeclampsia and other adverse outcomes.

Expanding Applications of NX Prenatal's Exosome-Based Diagnostics Platform Presented at Key Conferences

Retrieved on: 
Tuesday, November 13, 2018
Medicine, Clinical medicine, Medical tests, Biotechnology, Biopsy, Biomarkers, Molecular diagnostics, Exosome, Liquid biopsy, NX technology, Siemens NX

HOUSTON and LOUISVILLE,Ky., Nov. 13, 2018 /PRNewswire/ --NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that expanding applications of its proprietary NeXosome liquid biopsy platform were presented at recent scientific conferences.

Key Points: 
  • HOUSTON and LOUISVILLE,Ky., Nov. 13, 2018 /PRNewswire/ --NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that expanding applications of its proprietary NeXosome liquid biopsy platform were presented at recent scientific conferences.
  • Dr. Haas also presented methodological data demonstrating the effectiveness of the NeXosome platform in enriching maternal plasma samples for placental-derived exosomes, underscoring important "liquid biopsy" capabilities of NX Prenatal's technology platform.
  • NX Prenatal Inc. is a private, US-based molecular diagnostics company.
  • NX Prenatal has demonstrated the clinical utility of its biomarker panels for prenatal risk assessment as early as 10 weeks gestation.